CASI Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CASI Pharmaceuticals, Inc.
After a year of R&D collaboration, Otsuka has made a decision to acquire Canadian venture Mindset to further expand its neurological pipeline with new 5-HT2A agonists.
Plus deals from Huadong/Arcutis, SK Bioscience/Novavax, NeuroBio/MThera, CASI/Mundipharma/Acrotech, Amarin/Lotus and Synergy/Livzon.
Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.
Biocon subsidiary Syngene and Strides associate Stelis have entered a deal with the potential to change India’s vaccines and biologics landscape, as the former's growth plans are catapulted. Meanwhile, the Strides group gets to cut debt by selling a unit that made the ill-fated Sputnik Light COVID-19 vaccine and after Akston Biosciences terminated another COVID-19 vaccine alliance
- Other Names / Subsidiaries
- EntreMed, Inc.
- Miikana Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.